QD205 - RA Activity During Pregnancy (abstract #0955) #ACR22 28 yoF with active RA during Pregnancy - What are your treatment options? https://t.co/jj99qjugFG https://t.co/vioX8xZw0D

• https://bit.ly/3E0Rfi9

Dr PMease et al looked into impact of TNFi cycling in their #axSpA cohort: 💠After 6mos on 2nd TNFi, only 15% had ASDAS-LDA, 7% MCID in ASDAS, 8% >50% improvement 💠Cycling to 2nd TNFi limited benefits ⬇️sample size, worth further investigation #ACR22 @RheumNow ABST#1499 https://t.co/OVJxezdipW

Sjogren’s is tough to study, isn’t it? LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with: - ESSDAI (primary, obj dx activity) ✅ - auto-Ab ✅ - all patient outcomes ❎ Has already exceeded many attempts Even then, still some limitations ABST1113 #ACR22 @RheumNow https://t.co/NlBaFVuuPa

VEXAS Abs 0823 #ACR22: Pulmonary disease is common VEXAS, frequently pulmonary infiltrates. It remains unclear if respiratory manifestations are part of the primary disease or a co-existing condition. What are you seeing in clinical practice? @RheumNow https://t.co/VBVKLIrsqq https://t.co/QhxtCdNi5v

• Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammat…

Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's Will there be new Rx for Sjo? T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO Better ESSDAI at wk 24 (p=0.003) Unstim saliv flow: improved vs PBO, not stat signif Decreased CXCL13 chemokine PROs not improved @RheumNow https://t.co/hJp33JPpHt

FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR

• Characterization of Joint Distribution and Disease Burden in Patients with Earl…

"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO #ACR22 @RheumNow (credit: as heard by @drceowen) https://t.co/w88peUd4j1

Mx aging rheumatic dx pt 🌟5M approach🌟 🧠Mind (mood/cog) 💊 Medication (polypharm) 🏃 Mobility 👉Multicomplexity (biopsychsoc) 💪🏻 Matters (aligning 2 specific goals) 💥Interdisciplinary💥 #GeriRheum #ACR22 @RheumNow @B_Buehring_MD @UnaMakris

Read my new article on @RheumNow #ACR22 https://t.co/ByJ1yrrdj6

• SLE, Sex and STDs | RheumNow

DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…

#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY

Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain) Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR

Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

• Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Anky…

Interesting Abs 0825: MAS was most often caused 2nd to a benign disease. Most common presentation: fever w/ cytopenias. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 ass'd w/ higher mortality. #ACR22 @RheumNow https://t.co/HEuMedE9Rh https://t.co/6f4bf7x9Hh

• Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective St…